BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
154.74
+2.71 (1.78%)
At close: Jul 19, 2024, 4:00 PM
154.75
+0.01 (0.01%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
BeiGene Employees
BeiGene had 10,600 employees as of December 31, 2023. The number of employees increased by 1,400 or 15.22% compared to the previous year.
Employees
10,600
Change (1Y)
1,400
Growth (1Y)
15.22%
Revenue / Employee
$260,625
Profits / Employee
-$74,003
Market Cap
17.25B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10,600 | 1,400 | 15.22% |
Dec 31, 2022 | 9,200 | 1,000 | 12.20% |
Dec 31, 2021 | 8,200 | 2,900 | 54.72% |
Dec 31, 2020 | 5,300 | 1,941 | 57.79% |
Dec 31, 2019 | 3,359 | 1,289 | 62.27% |
Dec 31, 2018 | 2,070 | 1,170 | 130.00% |
Dec 31, 2017 | 900 | 552 | 158.62% |
Dec 31, 2016 | 348 | 108 | 45.00% |
Dec 31, 2015 | 240 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Labcorp Holdings | 67,000 |
Baxter International | 60,000 |
Quest Diagnostics | 48,000 |
Molina Healthcare | 18,000 |
The Cooper Companies | 15,000 |
Waters | 7,900 |
BioMarin Pharmaceutical | 3,401 |
Incyte | 2,524 |
BGNE News
- 4 days ago - BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer - Business Wire
- 5 weeks ago - BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 - Business Wire
- 5 weeks ago - BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region - Business Wire
- 6 weeks ago - BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL - Business Wire
- 2 months ago - BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 - Business Wire
- 2 months ago - BeiGene Reports First Quarter 2024 Financial Results and Business Updates - Business Wire
- 3 months ago - BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report - Business Wire